Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2455427-91-3
2. Azd-0780
3. 1-[6-[[(1s,3s)-3-[[5-(difluoromethoxy)pyrimidin-2-yl]amino]cyclopentyl]amino]pyridin-3-yl]pyridin-2-one
4. Schembl22241911
5. Gtpl13419
6. Azd0780
7. Nchuwrlotsaffn-kbpbesrzsa-n
8. Bdbm537931
9. Ex-a6975
10. Us11248001, Example 458b
11. Example 458b [us11248001b2]
12. Da-76642
13. Ms-27171
14. Hy-148673
15. Cs-0636856
| Molecular Weight | 414.4 g/mol |
|---|---|
| Molecular Formula | C20H20F2N6O2 |
| XLogP3 | 3.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 92.3 |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 641 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Cardiovascular Diseases.
Lead Product(s): Laroprovstat,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 02, 2025
Lead Product(s) : Laroprovstat,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AZD0780 Effect On LDL-C In ASCVD Patients Or At-Risk Individuals
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Cardiovascular Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2025
Details:
AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Cardiovascular Diseases.
Lead Product(s): Laroprovstat,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 02, 2025
Lead Product(s) : Laroprovstat,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AZD0780 On Major Adverse CV Events In High-Risk ASCVD Patients
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Cardiovascular Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2025
Details:
AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Heterozygous Familial Hypercholesterolemia.
Lead Product(s): Laroprovstat,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 02, 2025
Lead Product(s) : Laroprovstat,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients with HeFH
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Heterozygous Familial Hypercholesterolemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2025
Details:
AZD0780 is an oral, small molecule PCSK9 inhibitor that is being developed by AstraZeneca as an innovative therapy for patients with elevated low-density lipoprotein cholesterol (LDL-C) levels.
Lead Product(s): Laroprovstat,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2025
Lead Product(s) : Laroprovstat,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AZ's Oral PCSK9 Inhibitor halves Bad Cholesterol in Phase 2
Details : AZD0780 is an oral, small molecule PCSK9 inhibitor that is being developed by AstraZeneca as an innovative therapy for patients with elevated low-density lipoprotein cholesterol (LDL-C) levels.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2025
Details:
Rosuvastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Dyslipidemias.
Lead Product(s): Rosuvastatin Calcium,Laroprovstat
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 19, 2025
Lead Product(s) : Rosuvastatin Calcium,Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rosuvastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Dyslipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 19, 2025
Details:
AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dyslipidemias.
Lead Product(s): Laroprovstat,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2024
Lead Product(s) : Laroprovstat,Ezetimibe
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dyslipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2024
Details:
AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atherosclerosis.
Lead Product(s): Laroprovstat,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Fortrea
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2024
Lead Product(s) : Laroprovstat,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Fortrea
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Atherosclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 18, 2024
Details:
AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dyslipidemias.
Lead Product(s): Laroprovstat,Itraconazole
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 04, 2024
Lead Product(s) : Laroprovstat,Itraconazole
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dyslipidemias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 04, 2024
Details:
AstraZeneca will receive access to CSPC’s pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing in a range of cardiovascular disease.
Lead Product(s): YS2302018,Laroprovstat
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: AstraZeneca
Deal Size: $2,020.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement October 07, 2024
Lead Product(s) : YS2302018,Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : AstraZeneca
Deal Size : $2,020.0 million
Deal Type : Licensing Agreement
AstraZeneca Puts $2B on The Line for Preclinical Heart Disease Drug
Details : AstraZeneca will receive access to CSPC’s pre-clinical candidate small molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing in a range of cardiovascular disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $100.0 million
October 07, 2024
Details:
AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Diseases.
Lead Product(s): Laroprovstat,Inapplicable
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 19, 2024
Lead Product(s) : Laroprovstat,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AZD0780 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
89
PharmaCompass offers a list of Laroprovstat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Laroprovstat manufacturer or Laroprovstat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Laroprovstat manufacturer or Laroprovstat supplier.
PharmaCompass also assists you with knowing the Laroprovstat API Price utilized in the formulation of products. Laroprovstat API Price is not always fixed or binding as the Laroprovstat Price is obtained through a variety of data sources. The Laroprovstat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Laroprovstat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Laroprovstat, including repackagers and relabelers. The FDA regulates Laroprovstat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Laroprovstat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Laroprovstat supplier is an individual or a company that provides Laroprovstat active pharmaceutical ingredient (API) or Laroprovstat finished formulations upon request. The Laroprovstat suppliers may include Laroprovstat API manufacturers, exporters, distributors and traders.
Laroprovstat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Laroprovstat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Laroprovstat GMP manufacturer or Laroprovstat GMP API supplier for your needs.
A Laroprovstat CoA (Certificate of Analysis) is a formal document that attests to Laroprovstat's compliance with Laroprovstat specifications and serves as a tool for batch-level quality control.
Laroprovstat CoA mostly includes findings from lab analyses of a specific batch. For each Laroprovstat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Laroprovstat may be tested according to a variety of international standards, such as European Pharmacopoeia (Laroprovstat EP), Laroprovstat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Laroprovstat USP).
